All News

Biologic.choice.MD_.jpeg (keep)

Treatment Sequences Define Subphenotypes in RA Patients

d Jack Cush, MD

An analysis of a large rheumatoid arthritis cohort sheds light on biologic disease-modifying anti-rheumatic drugs (bDMARDs) clustering that may be used in management, as certain clusters of b/tsDMARD correlated with disease activity over time. 

Read Article
cost.price_.drugs_.pills_.jpg

Are bDMARDs, tsDMARDs and biosimilar DMARDs cost effective?

d Jack Cush, MD

Treatment advances with new biologic disease-modifying antirheumatic drugs (bDMARDs), targeted synthetic DMARDs (tsDMARDs) and biosimilar DMARDs (bsDMARDs) have proven efficacy and safety; but does their increased cost yield commensurate benefits in patients with rheumatoid arthritis (RA) and high disease activity?

Read Article
Cancer.risk_.jpg

Cancer Risk From RA, Not the Drugs

d Jack Cush, MD

While it is known that rheumatoid arthritis (RA) patients may be at risk for certain cancers, the question is which cancers and is this modified by therapy.

Read Article
computer screen safety

Abatacept Safety Outcomes Across 7 European Registries

d Jack Cush, MD

A multinational registry analysis of rheumatoid arthritis (RA) receiving abatacept (ABA) has shown that the safety profile of ABA remains unchanged with no new or increased risks of infection or malignancy.

Read Article
DECT.jpg

2023 EULAR Recommendations on Imaging in Crystal-Induced Arthritis

d Jack Cush, MD

New recommendations on imaging for crystal-induced (gout, CPPD) arthritis (CiA) were presented at EULAR 2023 in Milan.

Read Article
2023 EULAR Recommendations on Imaging in Crystal-Induced Arthritis These included 5 overarching principles & 10 recommendations on the role of imaging in making a diagnosis, monitoring, predicting, guiding therapy, and patient education in CiA. https://t.co/5WoIm8OPZs https://t.co/xqNxDvuymJ

Links:

Dr. John Cush RheumNow ( View Tweet)
RheumNow’s newly launched Poster Hall features sponsor-generated clinical trial posters designed to educate and inform. Posters addressing vasculitis, AxSpa and nrAxSpa, and PMR now available. https://t.co/0dV23VPDQH https://t.co/HfKhji40vU

Links:

Dr. John Cush RheumNow ( View Tweet)
Watch: Should you Assess Rheumatoid Factor Serially? Dr. Jack Cush discusses abstract OP0272 at EULAR 2023 in Milan, Italy. https://t.co/5e4SiPGDUM https://t.co/CzE597Auwg

Links:

Dr. John Cush RheumNow ( View Tweet)
Watch: De Novo Renal Nephritis Flares During Belimumab Trials Drs. Yuz Yusof and Iaonnis Parodis discuss abstract POS1156 at EULAR 2023 in Milan, Italy. https://t.co/XLzDF2VZ7Q https://t.co/iE16Ag3Rsu

Links:

Dr. John Cush RheumNow ( View Tweet)
How Often Do You Monitor MTX? Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow including new drug approval, a new SpA variant and new rules for methotrexate (MTX) monitoring and depression screening. https://t.co/niPFjQTenh https://t.co/JyL8t6EexT

Links:

Dr. John Cush RheumNow ( View Tweet)
Pediatric Rheumatologist Loan assistance repayment program from HSRA. A loan assistance of up to $100,000 to eligible pediatric medical subspecialists in exchange for a 3-year, full-time service commitment at an approved facility in an underserved area https://t.co/6oFkEEKAY9

Links:

Dr. John Cush RheumNow ( View Tweet)

Chronic Pain Management tools 1 Medication 2 Physical Therapy 3 Cognitive-Behavioral Therapy 4 Mindfulness Meditation 5 Acupuncture 6 Massage 7 Heat/Cold 8 TENS 9 Yoga/Tai Chi 10 Support groups https://t.co/VBvYR8VK16 https://t.co/tbfPnL1VEH

Links:

Dr. John Cush RheumNow ( View Tweet)
Using Optum claims data from 2009 to 2021, they identified 524 IgG4-RD pts (mean age 56 yrs), incidence increased over time 0.78 to 1.39/100K Pt Yrs 2015 and 2019. Prevalence (1/19) was 5.3/100K Pt-Yrs, w/ mortality rate 3.42/100 Pt-Yrs (HR 2.51) https://t.co/22eIjtC7kp https://t.co/8RlEtZiX9j

Links:

Dr. John Cush RheumNow ( View Tweet)
Rheums! Have a rheumatology question or case for Jack Cush? Record it here and we may feature it on an upcoming podcast. Tell us your name and where you practice rheumatology. https://t.co/3atPdJwb1m https://t.co/MKbgzEi9pd

Links:

Dr. John Cush RheumNow ( View Tweet)
NY Times article on a Moral Crisis for Americas doctors - the corporatization of Medicine leverages finances/incomes against physican values and practice preferences. Rheum Dr. Diana Girnita presents the Direct Medical Care option for MD autonomy https://t.co/TySD8l6I94 https://t.co/ZNTx7VVRfg

Links:

Dr. John Cush RheumNow ( View Tweet)
EULAR 2023 Notes from Milan https://t.co/cdmkiJmQrz https://t.co/w6UV85bFQ1

Links:

Dr. John Cush RheumNow ( View Tweet)
Watch: A Real Boost for Shingrix with JAKi Dr. David Liew discusses OP0225 presented at EULAR 2023 in Milan, Italy. https://t.co/Xgt85l6WgQ https://t.co/jPcA2GSFdm

Links:

Dr. John Cush RheumNow ( View Tweet)
ACR Concerned with MedPAC’s Cutting Part B Reimbursement ACR took issue with the orgs reco to Congress to keep a 6% add-on payment for the lowest-cost drugs, reduce the add-on payment for mid-to-high-level drugs, and add a payment cap for the $$$ drugs. https://t.co/IwZO88QThb https://t.co/GHjDwbHCCo

Links:

Dr. John Cush RheumNow ( View Tweet)
FAAH and FAAH-OUT - genes involved in pain perception; could these be the target of future therapies? Interesting article in FORBES bout role of FAAH and FAAH-OUT in pain. https://t.co/8FNvkVZy5R https://t.co/8Ldywt2wvq

Links:

Dr. John Cush RheumNow ( View Tweet)
Higher Genetic Loads Linked to Worse Systemic Lupus A study of a large SLE cohort shows by genomic analysis, that higher wGRS is associated with earlier SLE onset, higher anti–Sm antibody positivity, lupus nephritis and more diverse lupus manifestations. https://t.co/L8ZZEgcfNM https://t.co/elwDtDuSjP

Links:

Dr. John Cush RheumNow ( View Tweet)

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright 2024 All Rights Reserved.

×